305 related articles for article (PubMed ID: 9145744)
1. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years.
Berman JD
Clin Infect Dis; 1997 Apr; 24(4):684-703. PubMed ID: 9145744
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous leishmaniasis treatment.
Minodier P; Parola P
Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
[TBL] [Abstract][Full Text] [Related]
3. Practical guide for the treatment of leishmaniasis.
Davidson RN
Drugs; 1998 Dec; 56(6):1009-18. PubMed ID: 9878989
[TBL] [Abstract][Full Text] [Related]
4. Leishmaniasis.
Herwaldt BL
Lancet; 1999 Oct; 354(9185):1191-9. PubMed ID: 10513726
[TBL] [Abstract][Full Text] [Related]
5. [Therapy of leishmaniasis in France: consensus on proposed guidelines].
Buffet PA; Rosenthal É; Gangneux JP; Lightburne E; Couppié P; Morizot G; Lachaud L; Marty P; Dedet JP;
Presse Med; 2011 Feb; 40(2):173-84. PubMed ID: 21106333
[TBL] [Abstract][Full Text] [Related]
6. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study.
Soto J; Fuya P; Herrera R; Berman J
Clin Infect Dis; 1998 Jan; 26(1):56-8. PubMed ID: 9455509
[TBL] [Abstract][Full Text] [Related]
7. Advances in leishmaniasis.
Murray HW; Berman JD; Davies CR; Saravia NG
Lancet; 2005 Oct 29-Nov 4; 366(9496):1561-77. PubMed ID: 16257344
[TBL] [Abstract][Full Text] [Related]
8. The role of interferon-gamma in the treatment of visceral and diffuse cutaneous leishmaniasis.
Badaro R; Johnson WD
J Infect Dis; 1993 Mar; 167 Suppl 1():S13-7. PubMed ID: 8433014
[TBL] [Abstract][Full Text] [Related]
9. Challenges and new discoveries in the treatment of leishmaniasis.
Singh S; Sivakumar R
J Infect Chemother; 2004 Dec; 10(6):307-15. PubMed ID: 15614453
[TBL] [Abstract][Full Text] [Related]
10. Leishmaniasis: current status of available drugs and new potential drug targets.
Singh N; Kumar M; Singh RK
Asian Pac J Trop Med; 2012 Jun; 5(6):485-97. PubMed ID: 22575984
[TBL] [Abstract][Full Text] [Related]
11. The treatment of visceral leishmaniasis: safety and efficacy.
Jha RK; Sah AK; Shah DK; Sah P
JNMA J Nepal Med Assoc; 2013; 52(192):645-51. PubMed ID: 25327244
[TBL] [Abstract][Full Text] [Related]
12. Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals.
El-On J; Jacobs GP; Witztum E; Greenblatt CL
Antimicrob Agents Chemother; 1984 Nov; 26(5):745-51. PubMed ID: 6517557
[TBL] [Abstract][Full Text] [Related]
13. Leishmaniasis: recognition and management with a focus on the immunocompromised patient.
Choi CM; Lerner EA
Am J Clin Dermatol; 2002; 3(2):91-105. PubMed ID: 11893221
[TBL] [Abstract][Full Text] [Related]
14. Imported leishmaniasis: a heterogeneous group of diseases.
Pérez-Ayala A; Norman F; Pérez-Molina JA; Herrero JM; Monge B; López-Vélez R
J Travel Med; 2009; 16(6):395-401. PubMed ID: 19930379
[TBL] [Abstract][Full Text] [Related]
15. Visceral leishmaniasis - current therapeutic modalities.
Sundar S; Chatterjee M
Indian J Med Res; 2006 Mar; 123(3):345-52. PubMed ID: 16778315
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate.
Soto J; Hernandez N; Mejia H; Grogl M; Berman J
Clin Infect Dis; 1995 Jan; 20(1):47-51. PubMed ID: 7727669
[TBL] [Abstract][Full Text] [Related]
17. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis.
Berman JD; Wyler DJ
J Infect Dis; 1980 Jul; 142(1):83-6. PubMed ID: 6249874
[TBL] [Abstract][Full Text] [Related]
18. Leishmaniases and HIV/AIDS co-infections: review of common features and management experiences.
Ali A
Ethiop Med J; 2002 Apr; 40 Suppl 1():37-49. PubMed ID: 12802830
[TBL] [Abstract][Full Text] [Related]
19. [Experimental chemotherapy in cutaneous leishmaniasis. III. Effect of glucantime and humatin (P&D) on Leishmania garnhami and Leishmania braziliensis in hamsters].
Rezzano S; Armas JA; Moreno G; Scorza JV
Acta Cient Venez; 1984; 35(5-6):394-403. PubMed ID: 6537698
[No Abstract] [Full Text] [Related]
20. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma.
Badaro R; Falcoff E; Badaro FS; Carvalho EM; Pedral-Sampaio D; Barral A; Carvalho JS; Barral-Netto M; Brandely M; Silva L
N Engl J Med; 1990 Jan; 322(1):16-21. PubMed ID: 2104665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
